Business Wire

IFF Commissions Fragrance Ingredients Plant in China; Builds Industry Leadership; Sets New Sustainability Standards

Jaa

Regulatory News:

International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, is commissioning a new fragrance ingredients plant in Jiande, located in China’s Zhejiang Province. The plant underscores IFF’s commitment to the region and builds on the Company’s global presence for the sector. The new facility occupies approximately 165,000 square meters and will serve IFF customers globally.

“IFF has a legacy of innovation and excellence in fragrance ingredients. This long-planned investment underscores our continued commitment to providing our customers with the best possible products and service,” said Andreas Fibig, IFF Chairman and CEO. “Fully aligned with our strategic imperative to be our customers’ partner of choice, it does so as it furthers our quality, safety, and sustainability goals through the innovative use of technologies and the expertise of our people and partners.”

The plant was designed to help deliver on IFF’s strategic sustainability goals and to minimize its environmental impact with a special focus on areas of greatest sensitivity to the region. With Jiande’s growing population, the responsible use of water resources is paramount. As a result, the facility was designed to have the lowest water consumption per kilo of production in IFF’s operations network. In addition, a state-of-the-art odor abatement system was installed in collaboration with global experts to ensure the best-in-class environmental compliance. By leveraging the latest technologies available, the Company believes that from the first full year of production, the Jiande plant will be one of IFF’s most resource-efficient manufacturing locations globally.

IFF’s existing plant in China will serve as its center for training, teaching approximately 100 Chinese employees through 2018 in production skills, safety best practices, sustainability, and more. IFF’s employee base in China is the Company’s third largest globally.

“We are committed to leveraging our culture of excellence and innovation to ensure we attract the best and the brightest to IFF,” said Nicolas Mirzayantz, IFF Group President Fragrances, said, “We are proud of our 50-year history in the region, of contributing to our communities, and, of course, creating outstanding fragrance ingredients that are indispensable to the industry. The commissioning of the Jiande plant opens an exciting new chapter in our history in China and we look forward to a successful – and sustainable – future with our partners and people.”

# # #

Meet IFF

International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers taste, smell, or feel in fine fragrances and beauty, detergents and household goods, as well as beloved foods and beverages. Our 7,400 team members globally take advantage of leading consumer insights, research and development, creative expertise, and customer intimacy to develop differentiated offerings for consumer products. Learn more at www.iff.com, Twitter , Facebook, Instagram, and LinkedIn.

Contact information

International Flavors & Fragrances Inc.
Michael DeVeau, 212-708-7164
VP, Corporate Strategy, Investor Relations & Communications
Michael.DeVeau@iff.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Login VSI Announces Free Meltdown/Spectre Emergency Edition17.1.2018 11:00Tiedote

Today software solution provider Login VSI (www.loginvsi.com), the industry leader in VDI and DaaS performance testing, announces the temporary availability of a free, full-production, license of their flagship product Login VSI to every organization using Citrix XenApp, Citrix XenDesktop, VMware Horizon, or Microsoft Remote Desktop Services (RDS). This Emergency Edition will be free for all end-user organizations looking to test the performance impact of Meltdown and Spectre security patches, and will be valid until March 31, 2018. This license offers unlimited users, unlimited locations and includes all standard workloads. This special license can be requested through the Login VSI website, and through selected partners in Login VSI’s extensive eco-system of (VDI-performance supporting) software, hardware and service vendors. Login VSI also started a series of lab tests to quantify the exact performance impact of the Meltdown and Spectre patches rolled out today, and will keep doing

Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer17.1.2018 11:00Tiedote

Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, today announced that it has expanded its CE mark of the QuantideX® qPCR BCR-ABL IS Kit and QuantideX® qPCR BCR-ABL minor Kit to include clinical use on the Roche Diagnostics cobas z 480 Analyzer. The exquisite sensitivity and precision of the assays support clinicians in the rapidly evolving European clinical practice of therapy cessation for long-term responders on tyrosine kinase inhibitor (TKI) therapies. The available platforms, which also include the Applied Biosystems® 7500 Fast Dx Real-Time PCR instrument, improve the reach of the portfolio in Europe and Latin America. “As a global solutions provider, we are committed to ensuring that our best-in-class CML monitoring assays are widely available to deliver powerful answers that can impact patient decisions,” said Matthew McManus, M.D., Ph.

NTT Com Granted Microsoft's Gold Cloud Platform Status Globally17.1.2018 09:00Tiedote

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), is pleased to announce that it has been granted Microsoft Gold Cloud Platform status, the highest accreditation currently available, for its competency in delivering on quality, expertise and differentiated managed services in the cloud. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005911/en/ “Gold status is an important recognition of our competency in the cloud arena,” said Damian Skendrovic, CEO, NTT Com Managed Services. “With Microsoft Cloud Platform Competency we are helping enterprises to manage their hybrid cloud infrastructures, delivering on SaaS and PaaS solutions available in the Azure and Azure Stack marketplace that will enable our customers to optimize on performance and reach their business goals,” As part of its global strategy, NTT Com has been part of the early ado

Premas, IncellDx Ink India Distribution Agreement17.1.2018 08:01Tiedote

Premas Life Sciences Pvt., Ltd. and IncellDx, Inc. announced today they have signed an exclusive distribution agreement. The commercial partnership brings the power of cell by cell multiplex diagnostics for solid tumors carcinomas that can now be analyzed for molecular and protein biomarkers by flow cytometry. Included in the deal are: IncellDx's patented single-cell assays for quantifying PD-L1 on tumor cells and immune cell subtypes; patented single-cell assay for HPV E6, E7 mRNA detection in cervical samples; and, its incellPREP single-cell preparation kit for solid tissues including tumors. Researchers at AIIMS, New Delhi have completed a successful study utilizing IncellDx's next generation (3Dx) investigational molecular assay which quantifies E6, E7 mRNA overexpression in single cells simultaneously with the measurement of cell cycle and cell proliferation, the hallmark of progressive disease. Praveen Gupta, Managing Director of Premas Life Sciences commented: “India’s molecular

Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma17.1.2018 01:05Tiedote

Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) and Exelixis, Inc. (NASDAQ:EXEL) today announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma (HCC), which will be presented in a late-breaking oral session at the 2018 ASCO-GI Symposium being held in San Francisco, January 18-20, 2018. In CELESTIAL, cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival (OS), the trial’s primary endpoint, at the planned second interim analysis (prespecified critical p value ≤ 0.021) for the population of second- and third-line patients enrolled in this study. Median OS was 10.2 months with cabozantinib versus 8.0 months with placebo (HR 0.76, 95 percent CI 0.63-0.92; p=0.0049). Median progression-free survival (PFS) was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo (HR 0.44, 95 percent CI 0.36-0.52; p<0.0001). Objective resp

IFF to Release Fourth Quarter & Full Year 2017 Results February 1417.1.2018 00:15Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, announced that it will release its fourth quarter and full year 2017 earnings results following the market close on Wednesday, February 14, 2018. The management team will host a live webcast on Thursday, February 15, 2018 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumer

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme